Search Results - "Santana, Yasmarie"

  • Showing 1 - 14 results of 14
Refine Results
  1. 1

    Increased Expression of the RBPMS Splice Variants Inhibits Cell Proliferation in Ovarian Cancer Cells by Rabelo-Fernández, Robert J, Noriega Rivera, Ricardo A, Rivera, Yasmarie Santana, Tous-Beveraggi, José, Valiyeva, Fatima, Vivas-Mejia, Pablo E

    “…RNA-Binding Protein with Multiple Splicing (RBPMS) is a member of family proteins that bind to nascent RNA transcripts and regulate their splicing,…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    MicroRNA-92b targets tumor suppressor gene FBXW7 in glioblastoma by Grafals-Ruiz, Nilmary, Sánchez-Álvarez, Annelis O, Santana-Rivera, Yasmarie, Lozada-Delgado, Eunice L, Rabelo-Fernandez, Robert J, Rios-Vicil, Christian I, Valiyeva, Fatima, Vivas-Mejia, Pablo E

    Published in Frontiers in oncology (11-09-2023)
    “…Glioblastoma (GBM) is a highly aggressive and lethal primary brain tumor. Despite limited treatment options, the overall survival of GBM patients has shown…”
    Get full text
    Journal Article
  5. 5

    Decreased RBPMS Levels Promote Cell Proliferation, Invasion, Angiogenesis, in Cisplatin Resistant Ovarian Cancer Cells by Rabelo‐Fernandez, Robert, Santana, Yasmarie, Santiago, Ginette, Valiyeva, Fatma, Vivas‐Mejia, Pablo

    Published in The FASEB journal (01-05-2021)
    “…RBPMS is a RNA binding protein with multiple splicing encoded by the RBPMS gene located in chromosome eight in humans. Three major RBPMS isoforms have been…”
    Get full text
    Journal Article
  6. 6

    Abstract A68: Increasing intracellular glucose levels decreased expression of Enolase-I promoting cisplatin resistance in ovarian cancer cells by Rabelo-Fernandez, Robert J., Santana, Yasmarie, Grafals, Nilmary, Quiñones, Blanca, Santiago, Ginette, Lozada, Eunice, Reyes, Jeyshka, Vivas-Mejía, Pablo E.

    Published in Clinical cancer research (01-07-2020)
    “…Abstract Cytoreductive surgery in combination with platinum-based chemotherapy has been used for more than four decades for treat ovarian cancer. Although…”
    Get full text
    Journal Article
  7. 7

    Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer by Reyes-González, Jeyshka M, Quiñones-Díaz, Blanca I, Santana, Yasmarie, Báez-Vega, Perla M, Soto, Daniel, Valiyeva, Fatima, Marcos-Martínez, María J, Fernández-de Thomas, Ricardo J, Vivas-Mejía, Pablo E

    Published in Cancers (04-04-2020)
    “…Despite good responses to first-line treatment with platinum-based combination chemotherapy, most ovarian cancer patients will relapse and eventually develop…”
    Get full text
    Journal Article
  8. 8

    Decreased Expression of Enolase‐I Promotes Cisplatin Resistance of Ovarian Cancer Cells by Rabelo‐Fernández, Robert Joe, Vivas‐Mejia, Pablo, Santana‐Rivera, Yasmarie

    Published in The FASEB journal (01-04-2019)
    “…Platinum‐containing anticancer drugs has been used for more than four decades has effective treatment for ovarian cancer and many others solid tumors. However,…”
    Get full text
    Journal Article
  9. 9

    MicroRNA‐92b is a potential therapeutic target for Glioblastoma treatment by Grafals‐Ruiz, Nilmary, Lozada‐Delgado, Eunice, Santana‐Rivera, Yasmarie, Rivera‐Diaz, Monica, Valiyeva, Fatma, Vivas‐Mejía, Pablo

    Published in The FASEB journal (01-04-2019)
    “…Glioblastoma is the most aggressive type of primary brain tumor with an overall survival of 14.6 months with standard care treatment (surgery, radiotherapy,…”
    Get full text
    Journal Article
  10. 10

    Abstract 2538: MiR-92b targets FBXW7 in GBM cells by Sanchez-Alvarez, Annelis Odette, Grafals-Ruiz, Nilmary, Santana-Rivera, Yasmarie, Valiyeva, Fatma, Rosado-Rivera, Nathaly M., Vivas-Mejía, Pablo E.

    Published in Cancer research (Chicago, Ill.) (04-04-2023)
    “…Abstract MicroRNA (miRNA) dysregulation plays a central role in the initiation, progression, and drug resistance of virtually all cancer types. MiRNA-based…”
    Get full text
    Journal Article
  11. 11

    Targeting MicroRNA-143 Leads to Inhibition of Glioblastoma Tumor Progression by Lozada-Delgado, Eunice L, Grafals-Ruiz, Nilmary, Miranda-Román, Miguel A, Santana-Rivera, Yasmarie, Valiyeva, Fatma, Rivera-Díaz, Mónica, Marcos-Martínez, María J, Vivas-Mejía, Pablo E

    Published in Cancers (12-10-2018)
    “…Glioblastoma (GBM) is the most common and aggressive of all brain tumors, with a median survival of only 14 months after initial diagnosis. Novel therapeutic…”
    Get full text
    Journal Article
  12. 12
  13. 13
  14. 14